BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Repros Therapeutics Inc. 

2408 Timberloch Place
Suite B-7
The Woodlands  Texas  77380  U.S.A.
Phone: 281-719-3400 Fax: 281-719-3446


SEARCH JOBS










 Company News
Repros Therapeutics Inc. (RPRX) Release: Androxal® Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism 9/26/2014 7:16:45 AM
FDA Schedules Type B Pre-NDA Meeting With Repros Therapeutics Inc. (RPRX) 9/25/2014 2:24:54 PM
Repros Therapeutics Inc. (RPRX) Gives Update On Androxal® With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation At Biocentury 9/22/2014 8:11:03 AM
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014 6:09:13 AM
Repros Therapeutics Inc. (RPRX) Reports Second Quarter 2014 Financial Results 8/11/2014 7:51:03 AM
Repros Therapeutics Inc. (RPRX) Release: FDA Confirms Sperm And Testosterone Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel And Placebo 7/16/2014 7:40:19 AM
Repros Therapeutics Inc. (RPRX) Fully Enrolls Second Previously Announced Head To Head Study Of Androxal® Versus The Leading Topical Testosterone Gel 5/13/2014 11:39:36 AM
Repros Therapeutics Inc. (RPRX) Reports First Quarter 2014 Financial Results 5/12/2014 9:04:45 AM
Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel 4/30/2014 5:15:02 PM
Repros Therapeutics Inc. (RPRX) Fully Enrolls First Of Two Previously Announced Head To Head Studies Of Androxal® Versus The Leading Topical Testosterone Gel 4/14/2014 9:14:57 AM
12345678910...